Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MDGL
stocks logo

MDGL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
311.44M
+201.43%
0.050
-101.85%
312.25M
+127.51%
-0.191
-94.23%
357.93M
+68.2%
0.880
-146.32%
Estimates Revision
The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 8.58% over the past three months. During the same period, the stock price has changed by 35.42%.
Revenue Estimates for FY2025
Revise Upward
up Image
+8.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+22.1%
In Past 3 Month
Stock Price
Go Up
up Image
+35.42%
In Past 3 Month
Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 586.210
sliders
Low
392.00
Averages
543.25
High
650.00
Current: 586.210
sliders
Low
392.00
Averages
543.25
High
650.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$568 -> $620
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$568 -> $620
2025-11-21
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Madrigal Pharmaceuticals to $620 from $568 and keeps a Buy rating on the shares. The firm increased penetration assumptions for Rezdiffra after speaking with six key opinion leaders. The leaders reported "robust real-world uptake," with current F2/F3 penetration of liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis averaging 23% in high-volume centers and longer-term expectations of 10%-20%, the analyst tells investors in a research note. Despite pressure from weight loss drugs, the leaders view Rezdiffra as an "effective, liver-directed, oral backbone therapy with broader expansion possibilities based on the future F4c data," contends H.C. Wainwright.
Oppenheimer
Jay Olson
Outperform
maintain
$600 -> $650
2025-11-20
Reason
Oppenheimer
Jay Olson
Price Target
$600 -> $650
2025-11-20
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on Madrigal Pharmaceuticals to $650 from $600 and keeps an Outperform rating on the shares. The firm is encouraged by recent updates including several presentations at AASLD that strengthen Rezdiffra's profile and increase its enthusiasm for commercial opportunities in F2-F3 plus F4c patients.
Canaccord
Buy
maintain
$526 -> $587
2025-11-13
Reason
Canaccord
Price Target
$526 -> $587
2025-11-13
maintain
Buy
Reason
Canaccord raised the firm's price target on Madrigal Pharmaceuticals to $587 from $526 and keeps a Buy rating on the shares. The firm updated its model to reflec the impending launch of Rezdiffra in the EU as well as coming out of 3Q earnings.
H.C. Wainwright
Buy
maintain
$500 -> $568
2025-11-11
Reason
H.C. Wainwright
Price Target
$500 -> $568
2025-11-11
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Madrigal Pharmaceuticals to $568 from $500 and keeps a Buy rating on the shares. The company presented positive two-year data from the open-label compensated metabolic dysfunction-associated steatohepatitis cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial, the analyst tells investors in a research note. The firm says thestudy bolsters confidence for Rezdiffra's efficacy in compensated cirrhosis patients. It believes Rezdiffra should remain the default oral backbone as the field moves toward combination therapy.
Citizens JMP
Outperform
maintain
$485 -> $527
2025-11-05
Reason
Citizens JMP
Price Target
$485 -> $527
2025-11-05
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Madrigal Pharmaceuticals to $527 from $485 and keeps an Outperform rating on the shares. Rezdiffra sales of $287M beat consensus estimates, driven by robust demand, with more than 29,500 patients now on the therapy in the U.S., the analyst tells investors in a research note. The firm is looking forward to Madrigal's presence and MASH leadership at the Liver Meeting, which is kicking off later this week, where Rezdiffra will be featured in numerous presentations covering efficacy, safety, real-world use, quality of life improvements, early biomarkers, and durability of fibrosis regression.
Clear Street
Buy
maintain
$431 -> $533
2025-11-04
Reason
Clear Street
Price Target
$431 -> $533
2025-11-04
maintain
Buy
Reason
Clear Street raised the firm's price target on Madrigal Pharmaceuticals to $533 from $431 and keeps a Buy rating on the shares to reflect Rezdiffra's continued strong performance, even as Wegovy enters the F2-F3 MASH market. As a result of Rezdiffra's sustained growth, the firm has increased its peak penetration assumption to 20% from 15% for F2-F3 MASH, the analyst noted.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL.O) is 354.36, compared to its 5-year average forward P/E of -4.01. For a more detailed relative valuation and DCF analysis to assess Madrigal Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.01
Current PE
354.36
Overvalued PE
66.90
Undervalued PE
-74.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-21.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
37.67
Undervalued EV/EBITDA
-79.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
47.73
Current PS
0.00
Overvalued PS
147.20
Undervalued PS
-51.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.46% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MDGL News & Events

Events Timeline

(ET)
2025-11-10
08:18:24
Madrigal Pharmaceuticals unveils updated findings on Rezdiffra
select
2025-11-04 (ET)
2025-11-04
07:05:31
Madrigal Pharmaceuticals announces Q3 EPS of $5.08, up from $4.92 a year ago.
select
2025-08-20 (ET)
2025-08-20
05:43:00
Citizens JMP Increases Madrigal Pharmaceuticals Price Target to $485 from $483
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
05:10 AMNewsfilter
Madrigal Pharmaceuticals Grants Equity Awards to 24 New Employees Totaling 4,099 Shares
  • Equity Incentive Plan: On December 1, 2025, Madrigal Pharmaceuticals granted equity awards to 24 new non-executive employees, totaling 4,099 stock options and 14,630 restricted stock units, aimed at attracting talent and enhancing employee loyalty.
  • Incentive Structure: The granted options have an exercise price of $579.45 per share, equal to the closing price on the grant date, with vesting structured to occur in phases, where 25% vests after the first year and 6.25% quarterly thereafter, ensuring long-term employee retention.
  • Compliance Assurance: The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition.
  • Strategic Implications: By implementing this equity incentive plan, Madrigal not only enhances its ability to attract and retain key talent but also lays a foundation for long-term growth in the high-demand metabolic disease treatment sector.
[object Object]
Preview
4.0
11-22Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Madrigal Pharmaceuticals and Increases Price Target to $620

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
4.0
11-20Benzinga
Nvidia Set to Surge by 72%? Check Out 10 Leading Analyst Predictions for Thursday

  • Analyst Upgrades: Piper Sandler raised the price target for Global-E Online Ltd from $42 to $48 while maintaining an Overweight rating, with shares closing at $35.39.

  • Analyst Downgrades: HC Wainwright & Co. cut the price target for Agios Pharmaceuticals Inc from $56 to $48 but kept a Buy rating, with shares closing at $22.34.

  • Mixed Ratings: TD Cowen reduced the price target for Jack In The Box Inc from $21 to $16, maintaining a Hold rating, while Ascendiant Capital increased Aclarion Inc's target from $22 to $23, keeping a Buy rating.

  • Price Target Adjustments: Bernstein adjusted the price targets for several companies, raising Lowe's from $282 to $284 and cutting Target Corp from $87 to $80, while maintaining respective Outperform and Underperform ratings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Madrigal Pharmaceuticals Inc (MDGL) stock price today?

The current price of MDGL is 586.21 USD — it has increased 1.09 % in the last trading day.

arrow icon

What is Madrigal Pharmaceuticals Inc (MDGL)'s business?

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

arrow icon

What is the price predicton of MDGL Stock?

Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Madrigal Pharmaceuticals Inc (MDGL)'s revenue for the last quarter?

Madrigal Pharmaceuticals Inc revenue for the last quarter amounts to 287.27M USD, increased 362.03 % YoY.

arrow icon

What is Madrigal Pharmaceuticals Inc (MDGL)'s earnings per share (EPS) for the last quarter?

Madrigal Pharmaceuticals Inc. EPS for the last quarter amounts to -5.08 USD, increased 3.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Madrigal Pharmaceuticals Inc (MDGL)'s fundamentals?

The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 8.58% over the past three months. During the same period, the stock price has changed by 35.42%.
arrow icon

How many employees does Madrigal Pharmaceuticals Inc (MDGL). have?

Madrigal Pharmaceuticals Inc (MDGL) has 528 emplpoyees as of December 05 2025.

arrow icon

What is Madrigal Pharmaceuticals Inc (MDGL) market cap?

Today MDGL has the market capitalization of 13.31B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free